Quest Diagnostics stock hits all-time high at 182.43 USD

Quest Diagnostics (NYSE:DGX) stock reached an all-time high of 182.43 USD, marking a significant milestone for the $20.39 billion healthcare diagnostics company. According to InvestingPro analysis, the stock is currently trading slightly above its Fair Value, with notably low price volatility. This achievement comes amid a robust 1-year change of 20.79%, supported by impressive revenue growth of 12.58% and a solid P/E ratio of 21.47. The healthcare diagnostics firm has seen its stock price steadily rise, driven by increased demand for its services and positive market sentiment. This latest high underscores the company’s continued expansion and resilience in a competitive market, with InvestingPro data showing a "GOOD" overall financial health score and a 14-year track record of consecutive dividend increases. Discover 6 more exclusive InvestingPro Tips and comprehensive analysis in the Pro Research Report.

In other recent news, Quest Diagnostics reported strong financial results for the second quarter of 2025. The company announced adjusted earnings per share of $2.62, surpassing analyst estimates of $2.57. Additionally, Quest Diagnostics exceeded revenue expectations, posting $2.76 billion compared to the anticipated $2.73 billion. These results highlight the company’s solid performance in the recent quarter.

Furthermore, Quest Diagnostics’ subsidiary, Haystack Oncology, has entered into a research collaboration with Mass General Brigham. This partnership aims to study the use of liquid biopsy technology in guiding post-surgical treatment decisions for cancer patients. The collaboration will focus on two clinical trials involving specific types of skin and head and neck cancers. Researchers will evaluate the effectiveness of the Haystack MRD test in detecting minimal residual disease after treatment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.